Premium
A double‐blind comparative trial with mianserin and amitriptyline in outpatients with major depressive disorders.
Author(s) -
Feighner JP,
Jacobs RS,
Jackson RE,
Hendrickson G.,
Merideth CH,
O'Meara PD
Publication year - 1983
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1983.tb05870.x
Subject(s) - amitriptyline , mianserin , clinical global impression , anticholinergic , hamd , adverse effect , medicine , anesthesia , depression (economics) , clinical trial , psychology , psychiatry , antidepressant , placebo , significant difference , alternative medicine , macroeconomics , pathology , hippocampus , economics
1 A double‐blind trial with parallel treatment groups was conducted to compare the safety and efficacy of mianserin with amitriptyline. 2 This was a six week trial with weekly visits. Measurements at each visit included: 21 item Hamilton Depression (HAMD) Scale. Clinical Global Impression (CGI) Scale and Treatment Emergent Symptom Scale (TESS). 3 Mianserin and amitriptyline were comparable with respect to efficacy. 4 More adverse experiences were reported by amitriptyline patients. The predominant amitriptyline adverse experiences were of the anticholinergic type; the predominant mianserin adverse experience was drowsiness/fatigue. 5 The Efficacy Index (EI), a scale combining efficacy and adverse experiences, clearly demonstrated the superiority of mianserin over amitriptyline.